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EFFECTS OF COMBINED SONODYNAMIC AND PHOTODYNAMIC 
THERAPIES WITH PHOTOLON ON A GLIOMA C6 TUMOR MODEL
D.A. Tserkovsky*, E.N. Alexandrova, V.N. Chalau, Yu.Р. Istomin
N.N. Alexandrov National Cancer Center of Belarus, Minsk 223040, Belarus
The aim of this study was to investigate the low-power density sonication, sonodynamic therapy (SDT) with Photolon and combination 
of SDT and photodynamic therapy (PDT) with Photolon for the ablation of glioma C6 tumor model in rats. Methods: The study was 
performed on 50 rats bearing glioma C6. The tumors were sonicated with/without prior intravenous injection of photosensitizer (PS) 
Photolon (2.5 mg/kg b.w). Sonication was performed with 0.4; 0.7 and 1.0 W/cm² power density at 1 MHz frequency for 10 min, 
2.0 h after Photolon administration using BTL-5710 Sono (BTL Industries Limited, Great Britain). PDT was carried out 2.5 h after 
Photolon administration using diode laser with 661 nm wavelength (IMAF-AXICON, Minsk, Republic of Belarus) at doses of 50 and 
100 J/cm² with 0,17 W/cm² fluence rate. Assessment of tumor response was performed by vital staining with Evans blue and patho-
logic examination. Results: The maximal tumor necrosis area that underwent sonication (1 MHz; 0.7 W/cm²; 10 min.) followed by PDT 
at a dose of 100 J/cm² was 100%. Conclusion: This is the first report to demonstrate the benefits of sono-photodynamic therapy 
(SPDT) consisting of low-power density ultrasound and PDT for the treatment of malignant glioma models.
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Primary malignant brain tumors account for about 
1.5–2% of all human neoplasms and are distinctive 
of their ability for rapid proliferation, angiogenesis and 
invasive growth. Gliomas represent the most numerous 
category (77%) of central nervous system tumors. The 
principal nosologic forms of gliomas are astrocytomas 
(anaplastic astrocytoma, glioblastoma multiforme), oli-
godendrogliomas, ependimomas and mixed gliomas [1].
The conventional regimens of glioma therapy 
involve surgical intervention, radiotherapy, chemo-
therapy, immune correction therapy and specific 
antitumor immunotherapy. Nevertheless, despite the 
evident accomplishments of medical science over 
the past decades, the management of these patients 
largely remains an unsettled issue of current clinical 
neurooncology. The techniques used for the time 
being improve, at the best, their mean survival and 
prolong the recurrence-free period. The administered 
treatment is associated with high postoperative morta-
lity rates and the risk of severe morbidity development.
An active search is currently underway for new al-
ternative treatment techniques for malignant glial brain 
tumors. One of such techniques is sonodynamic thera-
py (SDT). SDT is based on a significant increase in drug 
cytotoxicity in the focal lesion exposed to ultrasound 
of 0.5–3.0 MHz frequency and 0.5–5.0 W/cm2 power 
density, resulting in cell destruction and killing [2–4]. 
The substances acquiring cancericidal abilities when 
affected by ultrasound are acknowledged as sonosen-
sitizers. Radiosensitizers (dimexide, metronidazole) 
and some chemotherapeutic agents (carboplatin, 
methotrexate and othes) are assigned to the sono-
sensitizer class in the first instance.
However, in the early 90s of the 20th century, two 
independent research groups (S. Umemura et al., 
1990; D. Kessel et al., 1994) reported their first re-
sults demonstrating the high efficacy of SDT with 
photosensitizers (PS) of the porphyrin series [5, 6]. 
At present, several theories are available, explaining 
the mechanisms underlying SDT. A number of authors 
hypothesized that PS sonomodification was based 
on photochemical reactions. However, ultrasound 
radiation of certain parameters is the trigger mecha-
nism of SDT rather than a light quantum [7]. According 
to V. Misik, the main acting element in its implementa-
tion is the phenomenon of cavitation realized on cel-
lular and subcellular levels [8].
The data of numerous studies have been currently 
published abroad, concerning the use of a number 
of 1st and 2nd generation PS (hematoporphyrin, pho-
tofrin I and II, meso- and protoporphyrin IX, ATX-70, 
pheophorbide-A, ALPcS4, chlorine PAD-S31 and e6, 
methylene blue, Rose Bengal, 5-ALA and others). The 
results of in vitro and in vivo trials suggest that SDT 
is a promising treatment modality for such malignant 
tumors as breast, lung, hepatic, intestinal and renal cell 
cancers, soft tissue sarcoma, ascetic forms of ovarian 
neoplasms, leukemias [9–13].
Over the recent years, SDT aroused certain interest 
as a novel and highly potential treatment modality for 
malignant gliomas. A number of experimental model 
studies obtained reassuring results of employing this 
modality in the treatment of different glial tumor strains 
with hematoporphyrin and Rose Bengal [14–16]. At the 
same time, a noticeable trend in research is combined 
employment of photodynamic therapy (PDT) and SDT 
in the management of glial tumors.
The primary purpose of this study is to investigate 
the antitumor effect of SDT and PDT with Photolon 
on a glioma C6 tumor model in white random-bred rats.
MATERIALS AND METHODS
Experimental animals and tumors. Fifty 
white random-bred rats obtained from the vivarium 
of the N.N. Alexandrov National Cancer Center of Belarus 
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(Minsk, Republic of Belarus) were used. The animals 
received a standard diet and had permanent access 
to water. Experimental rat glioma C6 was obtained from 
the tumor strains collection of the Russian Collection 
of Cell Cultures, Сytology Institute of Russian Academy 
of Sciences, St. Petersburg and was implanted in a se-
rial in mode. For experiments, tumor homogenate was 
implanted subcutaneously into the inguinal area by the in-
jection of 0.5 ml of 10% tumor cells suspension in Hanks’ 
solution. The experiments were performed 11–14 days 
after tumor implantation. Before the treatment the ani-
mals were anesthetized with droperidol (5.0 mg/kg) and 
fentanil (0.05 mg/kg) and immobilized. All manipulations 
were carried out according to the international scientific 
ethic standards of the quality of planning and carrying out 
animal investigations, according to “Methodic instruc-
tions for carrying out preclinical investigations of phar-
macokinetics of pharmacologic substances and drugs” 
presented in the “Guide lines for experimental (preclini-
cal) studies of new pharmacologic substances”(Health 
Ministry of Russian Federation, State Pharmacologic 
Committee of Russian Federation, Moscow, 2000).
PS. Chlorin e6 conjugated with polyvinyl pyrro-
lidone (Photolon® produced by Scientific Pharmaceuti-
cal Center of RUE “Belmedpreparaty”, Minsk, Republic 
of Belarus) was injected in the tail vein at standard 
dose of 2.5 mg/kg.
PDT. Photoirradiation of tumors was carried out 
2.5 h after Photolon administration using diode laser 
with 661 nm wavelength (IMAF-AXICON, Minsk, Re-
public of Belarus) at doses of 50 and 100 J/cm² with 
0.17 W/cm² fluence rate. The output was 0.3 W, the 
light spot diameter 1.5 cm, irradiation for 5 and 10 min.
SDT. Tumor insonation procedure was performed 
2.0 h after Photolon administration using BTL-
5710 Sono (BTL Industries Limited, Great Britain) with 
an emitter of 5.0 cm2, 1 MHz ultrasound frequency 
in a continuous mode with 0.4; 0.7 and 1.0 W/cm2 in-
tensity for 10 min employing stable techniques.
Sono-photodynamic therapy (SPDT). Tumor 
insonation procedure was performed 2.0 h after 
Photolon administration with 1 MHz ultrasound fre-
quency in a continuous mode with 0.4; 0.7 and 1.0 W/
cm2 power density  for 10 min. Photoirradiation of tu-
mors was delivered at doses of 50 and 100 J/cm² with 
0.17 W/cm² fluence rate. The output was 0.3 W, the 
light spot diameter 1.5 cm, irradiation for 5 and 10 min.
Antitumor efficacy of PDT/SDT with Photolon 
was evaluated 24 h after the treatment by quantifica-
tion of glioma C6 tumor necrosis area by vital staining 
of tumor bearing animals with 0.6% Evans’ blue solu-
tion. The animals were sacrificed by chloroform; the 
tumors were removed, fixed in 10% formalin solution 
and frozen. Transverse tumor sections 2–3 mm thick 
were made. Necrotic tumor areas due to direct effect 
on tumor cells or structural and functional disorders 
in microcirculation remained unstained. The percent-
age of tumor necrotic unstained parts was evaluated 
using “ImageJ” (NIH, Bethesda, USA). 
Statistical analysis. The values obtained were 
processed using standard statistical methods of Origin 
Stat 7.0 software. The significance level was deter-
mined as 0.05.
RESULTS AND DISCUSSION 
This study has made a comparative evaluation of an-
titumor efficacy of low power density ultrasound, SDT, 
PDT and their combination with prior i.v. introduction 
of Photolon. Local ultrasound treatment (1 MHz, 10 min) 
of the glioma C6 rat tumor model with 0.4, 0.7 and 
1.0 W/cm2 power density without prior PS administration 
caused tumor necrosis (44.62 ± 10.17%, 53.54 ± 5.23% 
and 66.27 ± 6.65% respectively) (Table 1, Fig. 1).
Table 1. Necrosis area in histotopographic sections of glioma C6 rat tu-
mor after ultrasound treatment with power density 0.4; 0.7 and 1.0 W/cm2
Groups Number of sections
Tumor 
area, cm2
Necrosis area
cm2 %
Ultrasound 0.4 W/cm2 12 3.67±1.73 1.64±0.34 44.62±10.17
Ultrasound 0.7 W/cm2 14 1.98±0.43 1.06±0.23 53.54±5.23
Ultrasound 1.0 W/cm2 12 2.42±0.27 1.61±0.32 66.27±6.65
Note: *p < 0.05
Table 2 and Fig. 2 present necrosis areas on histo-
topographic sections of glioma C6 after SDT (1 MHz, 
10 min) with 0.4, 0.7 and 1.0 W/cm2 power density, 
ultrasound treatment being performed 2 hours after 
Photolon administration at a dose of 2.5 mg/kg. The 
percentage of tumor necrosis areas was 61.04 ± 4.77%, 
82.65 ± 2.41% and 79.71 ± 4.66% respectively).
Table 2. Necrosis area in histotopographic sections of glioma C6 rat tu-
mor after i.v. injection of  Photolon at a dose  of 2.5 mg/kg and ultrasound 
irradiation with power density 0.4; 0.7 and 1.0 W/cm2
Groups Number of sections
Tumor 
area, cm2
Necrosis area
cm2 %
Photolon + Ultrasound 
0.4 W/cm2
11 2.92±0.21 1.78±0.13 61.04±4.77
Photolon + Ultrasound 
0.7 W/cm2
12 2.78±0.52 2.21±0.27 82.65±2.41
Photolon + Ultrasound 
1.0 W/cm2
13 4.37±0.83 3.48±0.35 79.71±4.66
Note: *p < 0.05
A significant increase in the values under study was 
noted in rats treated with SDT vs controls (ultrasound 
therapy without prior PS administration) (p < 0.05). 
Table 3 and Fig. 3 demostrate necrosis areas on his-
totopographic sections of glioma C6 after PDT at light 
exposure doses of 50 and 100 J/cm2 (0.17 W/ cm2 pow-
er density). The percentage of tumor necrosis areas 
was 61.42 ± 2.62% and 85.52 ± 3.79% respectively.
Table 3. Necrosis area in histotopographic sections of glioma C6 rat tu-
mor after i.v. injection of Photolon at a dose of 2.5 mg/kg and photoirradi-
ation at doses of 50 and 100 J/cm2
Groups Number of sections
Tumor 
area, cm2
Necrosis area
cm2 %
Photolon + Photoirradia-
tion 50 J/cm2
10 3.46±0.21 2.13±0.17 61.42±2.62
Photolon + Photoirradia-
tion 100 J/cm2
12 4.01±0.19 3.43±0.16 85.52±3.79
Note: *p < 0.05
On 22 histotopographic sections, Table 4 and Fig. 
4 present the results of combination treatment us-
ing local ultrasound radiation with 0.7 W/cm2 power 
density and local photoirradiation of tumors at 50 and 
100 J/cm2 light exposure doses respectively.
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Table 4. Histotopographic sections of glioma C6 rat tumor after SDT with 
power density 0.7 W/cm2 and PDT at doses of 50 (a) and 100 (b) J/cm2
Groups Number of sections
Tumor 
area, cm2
Necrosis area
cm2 %
Photolon + Ultrasound 
0.7 W/cm2 + Photoirra-
diation 50 J/cm2
10 3.87±0.14 3.31±0.18 85.64±5.33
Photolon + Ultrasound 
0.7 W/cm2 + Photoirra-
diation 100 J/cm2
12 4.33±0.16 4.33±0 100
Note: *p < 0.05
The results obtained suggest that combination 
treatment including SDT and PDT of certain parameters 
enhances the effect on the glial tumor model in rat brain. 
The combination treatment significally (by 25–30%) 
increases necrosis areas in tumor tissues compared 
with each of the components taken separately. The 
optimal therapy regimen involves local 1 MHz frequency 
ultrasound with 0.7 W/cm2 power density and photoir-
radiation at a light exposure dose of 100 J/cm2 after 
prior i.v. Photolon administration at a dose of 2.5 mg/kg.
SDT for malignant glial tumors is a novel and 
promising trend in neurooncology. At the given stage 
of its formation the profile of this treatment modality 
is experimental. A number of in vivo studies reported 
promising results of its use in the management of rat 
gliomas with such sonosensitizers as hematoporphy-
rin, Rose Bengal and others [15, 16]. 
Our trial of laboratory rats with glioma C6 has reaf-
firmed sonosensitizing activity of Photolon, thus being 
a drug of prospective advantages for SDT of glial brain 
tumors. We have found evidence suggesting that the 
combined employment of ultrasound and the photo-
sensitizing agent leads to strong damage of tumor 
tissue as a result of developing induced chemical 
reactions and cavitation effect implementation in the 
a b c
Fig. 1. Histotopographic sections of glioma C6 rat tumor after ultrasound treatment with power density 0.4 (a); 0.7 (b) and 1.0 (c) W/cm2
a b c
Fig. 2. Histotopographic sections of glioma C6 rat tumor after SDT with power density 0.4 (a); 0.7 (b) and 1.0 (c) W/cm2
a b
Fig. 3. Histotopographic sections of glioma C6 rat tumor after 
PDT at doses of 50 (a) and 100 (b) J/cm2
a b
Fig. 4. Histotopographic sections of glioma C6 rat tumor after 
SDT with power density 0.7 W/cm2 and PDT at doses of 50 (a) 
and 100 (b) J/cm2
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tumor cell. The use of low power density mode of ul-
trasound treatment is safe, and possible application 
in the clinical setting would not be associated with 
high risk of thermal damage of normal brain tissues. 
A promising lead for further research is evaluation 
of antitumor efficacy of combined ultrasound and laser 
radiation treatment in the management of glial brain 
tumors (SPDT). Our encouraging results and the few 
reports in this field allow to define the SPDT modality 
as a growing trend in current neurooncology. 
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